At a glance

ClinicalIndex Comparison Record

N/ACompleted· 28 enrolled

Drug / intervention

Inotuzumab Ozogamicindrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04456959

NCT04456959N/ACompleted

Compare CT.gov

A Retrospective Chart Review of UK Patients With Relapsed/Refractory Acute Lymphoblastic Leukaemia Treated With Inotuzumab Ozogamicin, a Real World Research Study

Pfizer·observational·Posted Jul 7, 2020·Updated Sep 28, 2022

In Brief

An observational study evaluating Inotuzumab Ozogamicin for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Completed, enrolled 28 participants across 4 sites.

Detailed Summary

The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

CountriesUnited Kingdom

Collaborators--

Timeline

N/ACompletedFinished

2020202120222023202420252026

Enrollment StartJan 2020

First PostedJul 2020

Primary CompletionJan 2021

TodayJul 2026

First PostedJul 7, 2020

Enrollment StartJan 6, 2020

Primary CompletionJan 27, 2021

TodayJul 2, 2026

Enrollment to primary: 1.1 yearsPosted 6.0 years ago

Interventions

Inotuzumab Ozogamicindrug

Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.